Bachem Holding AG stock (CH0012530207): Swiss biotech screens strong fundamentals

Bachem Holding AG, a leader in peptide and oligonucleotide manufacturing, shows robust metrics with a 6.1B market cap and 28.7% growth in the STOXX 600 screener as of recent data.

Bachem Holding AG continues to draw attention from European stock screeners, highlighting its position in the healthcare sector with a market capitalization of 6.1 billion CHF, forward P/E of 31.1 and EV/EBITDA of 27.2, according to Midgard Finance STOXX 600 screener. The company, listed on the Swiss Exchange (SIX: BANB), specializes in developing and manufacturing peptides for pharmaceutical and biotech applications, serving global markets including the US.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Healthcare / Peptide manufacturing
• Headquarters/country: Switzerland
• Core markets: Europe, US, Asia
• Key revenue drivers: Custom peptide synthesis, oligonucleotides
• Home exchange/listing venue: SIX Swiss Exchange (BANB)
• Trading currency: CHF

Bachem Holding AG: core business model

Bachem Holding AG develops and manufactures peptides and oligonucleotides, focusing on custom synthesis for pharmaceutical research, development and commercial production. The company operates production sites in Switzerland, the US and Europe, enabling it to serve major biotech and pharma clients globally. Bachem's business model emphasizes innovation in complex peptide manufacturing, which is critical for drugs in oncology, endocrinology and other therapeutic areas, as described on its official website.

With a vertically integrated approach, Bachem handles everything from lab-scale synthesis to GMP-compliant large-scale production. This positions it as a key supplier in the growing peptide therapeutics market, where demand is driven by advancements in drug delivery and biologics. US investors note Bachem's California facility, which supports North American clients and contributes to exposure in the US biotech ecosystem.

Main revenue and product drivers for Bachem Holding AG

Revenue stems primarily from catalog and custom peptides, with oligonucleotides gaining traction amid rising mRNA and gene therapy needs. The healthcare sector listing underscores Bachem's 28.7% growth metric and 18.3% margins in recent screener data from Midgard Finance. Key drivers include partnerships with Big Pharma for blockbuster peptide drugs and expanding oligonucleotide services.

Historical performance shows resilience; three years ago, shares traded at 94.45 CHF on SIX Swiss Exchange, per Finanzen.net as of recent review. Growth in peptide APIs for GLP-1 agonists and other incretin mimetics bolsters revenue, with US market exposure via sales to domestic biotech firms.

Industry trends and competitive position

The peptide manufacturing sector benefits from surging demand for peptide-based therapeutics, projected to grow amid obesity drug booms and peptide vaccines. Bachem competes with Lonza and PolyPeptide Group but differentiates through scale and regulatory expertise. Its inclusion in STOXX 600 highlights fundamentals attractive to institutional investors tracking European healthcare.

Why Bachem Holding AG matters for US investors

Bachem's US production site in Torrance, California, facilitates supply to American pharma giants, linking it directly to US biotech innovation. Listed on SIX, shares are accessible via US brokers, offering diversification into Swiss precision manufacturing with US revenue ties. Fundamentals like 6.1B market cap appeal to those eyeing global peptide supply chains.

Conclusion

Bachem Holding AG maintains a solid profile in peptide and oligonucleotide production, with strong screener fundamentals and global reach including US operations. Recent data points to growth potential in healthcare, though investors monitor Swiss Exchange performance amid biotech volatility. The company's specialized manufacturing supports key drug pipelines worldwide.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.